MGMT and neoplasm: Key molecular biomarkers including isocitrate dehydrogenase (IDH) mutation, 1p/19q chromosomal co-deletion, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and WHO tumor grade significantly influence clinical outcomes and treatment response.